1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR

CXCR

CXC chemokine receptors; C-X-C motif chemokine receptors

CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144783
    CXCR2 antagonist 6
    Antagonist
    CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC50=0.044 µM) and calcium mobilization (IC50=0.66 µM)[ 1].
    CXCR2 antagonist 6
  • HY-RS03398
    Cxcr1 Mouse Pre-designed siRNA Set A
    Inhibitor

    Cxcr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr1 Mouse Pre-designed siRNA Set A
    Cxcr1 Mouse Pre-designed siRNA Set A
  • HY-P1102A
    TC14012 TFA
    Modulator
    TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 TFA is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity.
    TC14012 TFA
  • HY-139906
    CXCL12 ligand 1
    Agonist
    CXCL12 ligand 1 is the first ligand of the sY12-binding pocket on chemokine CXCL12.
    CXCL12 ligand 1
  • HY-101407R
    Nicotinamide N-oxide (Standard)
    Antagonist
    Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
    Nicotinamide N-oxide (Standard)
  • HY-144781
    CXCR2 antagonist 5
    Antagonist
    CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC50=0.013 µM) and calcium mobilization (IC50=0.1 µM)[ 1].
    CXCR2 antagonist 5
  • HY-18981R
    Decursin (Standard)
    Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities[4].
    Decursin (Standard)
  • HY-146053
    CXCR4 modulator-1
    Modulator
    CXCR4 modulator-1 (compound ZINC72372983) is a potent CXCR4 modulator with an EC50 value of 100 nM. CXCR4 modulator-1 can be used for researching anti-inflammatory, anticancer and anti-HIV.
    CXCR4 modulator-1
  • HY-P4911
    SDF-1α (human)
    Modulator
    SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research.
    SDF-1α (human)
  • HY-P4911A
    SDF-1α (human) (TFA)
    Modulator
    SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research.
    SDF-1α (human) (TFA)
  • HY-146372
    CXCR4 antagonist 5
    Antagonist
    CXCR4 antagonist 5 (compound 23) is a highly potent CXCR4 antagonist with an IC50 value of 8.8 nM. CXCR4 antagonist 5 can inhibit CXCL12-induced cytosolic calcium increase (IC50 = 0.02 nM) and inhibits CXCR4/CXLC12-mediated chemotaxis. CXCR4 antagonist 5 has good physicochemical properties and in vitro safety profiles, inhibiting CYP isozymes and hERG marginally or moderately.
    CXCR4 antagonist 5
  • HY-10017A
    (R)-SCH 546738
    99.75%
    (R)-SCH 546738 is the R-isomer of SCH 546738 (HY-10017). SCH 546738 is an orally active and non-competitive antagonist for CXCR3 with Ki of 0.4 nM for human CXCR3 receptor.
    (R)-SCH 546738
  • HY-147979
    CXCR4 antagonist 9
    Antagonist
    CXCR4 antagonist 9 (Compound 2) is a CXCR4 antagonist with an IC50 of 15 nM. CXCR4 antagonist 9 inhibits CXCL12 induced cytosolic calcium increase with an IC50 of 1.3 nM.
    CXCR4 antagonist 9
  • HY-144286
    CXCR4 antagonist 3
    Inhibitor
    CXCR4 antagonist 3 (compound 12a) is a potent antagonist of CXCR4 with an IC50 of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus.
    CXCR4 antagonist 3
  • HY-149558
    CXCR4-IN-2
    Inhibitor
    CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule that is a potent CXCR4 inhibitor with anticancer activity. CXCR4-IN-2 has cytotoxic (IC50: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. CXCR4-IN-2 induces cell arrest in the G2/M phase and induces apoptosis.
    CXCR4-IN-2
  • HY-158317
    SFB-AMD3465
    SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine.
    SFB-AMD3465
  • HY-P5923
    E70K
    E70K is a CXCL8 C-terminal peptide with a substitution of glutamic acid (E) 70 with lysine (K). E70K can reduce neutrophil adhesion and migration during inflammation.
    E70K
  • HY-168531
    EMU-116
    Antagonist
    EMU-116 is an orally active CXCR4 antagonist. EMU-116 can be used in the study of cancer.
    EMU-116
  • HY-RS03397
    CXCR1 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR1 Human Pre-designed siRNA Set A
    CXCR1 Human Pre-designed siRNA Set A
  • HY-144285
    CXCR4 antagonist 4
    Antagonist
    CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM).
    CXCR4 antagonist 4
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.